ClinicalTrials.gg
Sign In

Drug

Bcl-2 Inhibitor TQB3909 clinical trials

studies test it
7
open now
5
in phase 3
1
first study started
2022

Keep track of what changes. Save the Bcl-2 Inhibitor TQB3909 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TQB3909 tablets
5

Written with another drug

TQB3909 Tablets + Azacitidine
1

Studies by the year they started

7 studies that test it; most in 2023 (3)

Studies that test Bcl-2 Inhibitor TQB3909, by start year
YearStudies
20221
20233
20242
20261

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
3
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Lymphoma
1
Breast Neoplasms
1

Who runs them

Industry 7 · Other 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (7)

Often tested with

Tested in the same studies.

BTK Inhibitor TQB3702 (1) · Azacitidine (1)

Studies

Open first, then newest update. How each study uses Bcl-2 Inhibitor TQB3909 is read from its arms, and is right about nine times in ten.

Testing it · 7

Given in every arm · 1 — Bcl-2 Inhibitor TQB3909 is usual care beside what is tested